The development of automated patch clamp assays for canonical transient receptor potential channels TRPC3, 6, and 7

Assay and Drug Development Technologies

Volumn 12, Issue 5, 2014, Pages 282-292

  McPate, Mark ^a   Bhalay, Gurdip ^a   Beckett, Martin ^a   Fairbrother, Sian ^a   Gosling, Martin ^a   Groot Kormelink, Paul J ^a   Lane, Rebecca ^a,b   Kent, Toby ^a   Van Diepen, Michiel T ^a   Tranter, Pamela ^a   Verkuyl, J Martin ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M3 RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL 7; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, HUMAN; TRPC7 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; MEDICAL DEVICE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP DEVICE; PATCH CLAMP TECHNIQUE; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOMATION; CELL CULTURE; CHO CELL LINE; CRICETULUS; HIGH THROUGHPUT SCREENING; HUMAN; KINETICS; METABOLISM; PROCEDURES;

ANIMALS; AUTOMATION; CELLS, CULTURED; CHO CELLS; CRICETULUS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS; PATCH-CLAMP TECHNIQUES; TRPC CATION CHANNELS;

EID: 84902515164     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2014.574     Document Type: Article

References (52)

1. Clapham DE, Montell C, Schultz G, Julius D: International Union of Pharmacology. XLIII. Compendium of voltage-gated ion channels: transient receptor potential channels. Pharmacol Rev 2003;55:591-596.
2. Song MY, Yuan JX: Introduction to TRP channels: structure, function, and regulation. Adv Exp Med Biol 2010;661:99-108.
3. Ramsey IS, Delling M, Clapham DE: An introduction to TRP channels. Annu Rev Physiol 2006;68:619-647.
4. Eder P, Poteser M, Groschner K: TRPC3: a multifunctional, pore-forming signalling molecule. Handb Exp Pharmacol 2007;179:77-92.
5. Dietrich A, Gudermann T: Trpc6. Handb Exp Pharmacol 2007;179:125-141.
6. Numaga T, Wakamori M, Mori Y: Trpc7. Handb Exp Pharmacol 2007;179:143-151.
7. Beech DJ: Characteristics of transient receptor potential canonical calciumpermeable channels and their relevance to vascular physiology and disease. Circ J 2013;77:570-579.
8. Estacion M, Li S, Sinkins WG, et al.: Activation of human TRPC6 channels by receptor stimulation. J Biol Chem 2004;279:22047-22056.
9. Estacion M, Sinkins WG, Jones SW, Applegate MA, Schilling WP: Human TRPC6 expressed in HEK 293 cells forms non-selective cation channels with limited Ca2+ permeability. J Physiol 2006;572(Pt 2):359-377.
10. Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann T, Schultz G: Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 1999;397:259-263.
11. Harteneck C, Gollasch M: Pharmacological modulation of diacylglycerolsensitive TRPC3/6/7 channels. Curr Pharm Biotechnol 2011;12:35-41.
12. Bon RS, Beech DJ: In pursuit of small molecule chemistry for calciumpermeable non-selective TRPC channels-mirage or pot of gold? Br J Pharmacol 2013;170:459-474.
13. Trebak M: Canonical transient receptor potential channels in disease: targets for novel drug therapy? Drug Discov Today 2006;11:924-930.
14. Preti D, Szallasi A, Patacchini R: TRP channels as therapeutic targets in airway disorders: a patent review. Expert Opin Ther Pat 2012;22:663-695.
15. Bush EW, Hood DB, Papst PJ, et al.: Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem 2006;281:33487-33496.
16. Liu D, Scholze A, Zhu Z, et al.: Increased transient receptor potential channel TRPC3 expression in spontaneously hypertensive rats. Am J Hypertens 2005; 18:1503-1507.
17. Liu D, Yang D, He H, et al.: Increased transient receptor potential canonical type 3 channels in vasculature from hypertensive rats. Hypertension 2009;53:70-76.
18. Thilo F, Loddenkemper C, Berg E, Zidek W, Tepel M: Increased TRPC3 expression in vascular endothelium of patients with malignant hypertension. Mod Pathol 2009;22:426-430.
19. Walz G: Slit or pore? A mutation of the ion channel TRPC6 causes FSGS. Nephrol Dial Transplant 2005;20:1777-1779.
20. Winn MP, Conlon PJ, Lynn KL, et al.: A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005;308:1801-1804.
21. Heeringa SF, Moller CC, Du J, et al.: A novel TRPC6 mutation that causes childhood FSGS. PLoS One 2009;4:e7771.
22. Zhu B, Chen N, Wang ZH, et al.: Identification and functional analysis of a novel TRPC6 mutation associated with late onset familial focal segmental glomerulosclerosis in Chinese patients. Mutat Res 2009;664:84-90.
23. Yu Y, Fantozzi I, Remillard CV, et al.: Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A 2004;101:13861-13866.
24. Yu Y, Keller SH, Remillard CV, et al.: A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation 2009;119:2313-2322.
25. Washburn DG, Holt DA, Dodson J, et al.: The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilinothiazole pharmacophore. Bioorg Med Chem Lett 2013;23:4979-4984.
26. Seo K, Rainer PP, Shalkey Hahn V, et al.: Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc Natl Acad Sci U S A 2014;111:1551-1556.
27. Liu K, Samuel M, Harrison RK, Paslay JW: Rb + efflux assay for assessment of non-selective cation channel activities. Assay Drug Dev Technol 2010;8: 380-388.
28. Miller M, Wu M, Xu J, Weaver D, Li M, Zhu MX: High-throughput screening of trpc channel ligands using cell-based assays. In: TRP Channels. Zhu MX (ed)., pp 1-22. CRC Press, Boca Raton, FL, 2011.
29. Terstappen GC, Roncarati R, Dunlop J, Peri R: Screening technologies for ion channel drug discovery. Future Med Chem 2010;2:715-730.
30. Wickenden A, Priest B, Erdemli G: Ion channel drug discovery: challenges and future directions. Future Med Chem 2012;4:661-679.
31. Bibette J: Gaining confidence in high-throughput screening. Proc Natl Acad Sci U S A 2012;109:649-650.
32. Asmild M, Oswald N, Krzywkowski KM, et al.: Upscaling and automation of electrophysiology: toward high throughput screening in ion channel drug discovery. Receptors Channels 2003;9:49-58.
33. Mathes C: QPatch: the past, present and future of automated patch clamp. Expert Opin Ther Targets 2006;10:319-327.
34. Chambard JM, Tagat E, Boudeau P, Partiseti M: Transforming TRP channel drug discovery using medium-throughput electrophysiological assays. J Biomol Screen 2013;19:468-477.
35. Milligan CJ, Moller C: Automated planar patch-clamp. Methods Mol Biol 2013; 998:171-187.
36. Castle N, Printzenhoff D, Zellmer S, Antonio B,Wickenden A, Silvia C: Sodiumchannel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb Chem High Throughput Screen 2009;12:107-122.
37. Schroeder K, Neagle B, Trezise DJ, Worley J: Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 2003;8:50-64.
38. Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R: High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov 2008;7:358-368.
39. Farre C, Fertig N: HTS techniques for patch clamp-based ion channel screening-Advances and economy. Expert Opin Drug Discov 2012;7:515-524.
40. Sykes DA, Dowling MR, Charlton SJ: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 2009;76:543-551.
41. Philipps B, Forstner M, Mayr LM: A baculovirus expression vector system for simultaneous protein expression in insect and mammalian cells. Biotechnol Prog 2005;21:708-711.
42. Katso RM, Parham JH, Caivano M, et al.: Evaluation of cell-based assays for steroid nuclear receptors delivered by recombinant baculoviruses. J Biomol Screen 2005;10:715-724.
43. Finkel A, Wittel A, Yang N, Handran S, Hughes J, Costantin J: Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol Screen 2006;11:488-496.
44. +channels. J Biomol Screen 2007;12:50-60.
45. Dale TJ, Townsend C, Hollands EC, Trezise DJ: Population patch clamp electrophysiology: a breakthrough technology for ion channel screening. Mol Biosyst 2007;3:714-722.
46. +entry. J Biol Chem 1998;273:133-142.
47. +)-permeable cation channel. Circ Res 2001; 88:325-332.
48. Boulay G, Zhu X, Peyton M, et al.: Cloning and expression of a novel mammalian homolog of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the Gq class of G protein. J Biol Chem 1997;272:29672-29680.
49. Follman MGP, Hachtel S, Hessler G, Kleemann HW, Maier T, Mc Cort G, Struebing C, Thiers B, Wang LH, Follman MGP, Hachtel S, Hessler G, Kleemann HW, Maier T, Mc Cort G, Struebing C, Thiers B, Wang LH, Follman MGP, Hachtel S,Hessler G, Kleemann HW,Maier T,Mc Cort G, Struebing C, Thiers B,Wang LH: Derivatives of aminoindanes, their preparation and their application in therapeutics, WO 2011/107474, 2011.
50. Dodson JMJ, Mcatee J, Terrell L, Washburn D, Dodson JMJ, Mcatee J, Terrell L, Washburn D, Dodson JMJ, Mcatee J, Terrell L, Washburn DS, WO 2012/037349, 2012.
51. Graef JD, Benson LC, Sidach SS, et al.: Validation of a high-throughput, automated electrophysiology platform for the screening of nicotinic agonists and antagonists. J Biomol Screen 2013;18:116-127.
52. Gillie DJ, Novick SJ, Donovan BT, Payne LA, Townsend C: Development of a high-throughput electrophysiological assay for the human ether-A-go-go related potassium channel hERG. J Pharmacol Toxicol Methods 2013;67:33-44.